Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 3Thoracic 2Plasma cell 2Gynecologic 2Genitourinary 2Gastrointestinal 2Breast 2Other hematologic neoplasm 1Lymphoid 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 328Lung Neoplasms 158Pancreatic Neoplasms 30Adenocarcinoma of Lung 27Colorectal Neoplasms 26Neoplasms 24Small Cell Lung Carcinoma 21Breast Neoplasms 17Neoplasm Metastasis 15Mesothelioma, Malignant 14Ovarian Neoplasms 12Adenocarcinoma, Bronchiolo-Alveolar 12Mesothelioma 10Stomach Neoplasms 9Colonic Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Carcinoma 8Urinary Bladder Neoplasms 7Triple Negative Breast Neoplasms 7Sarcoma 7Prostatic Neoplasms 7Head and Neck Neoplasms 7Rectal Neoplasms 6Non-Squamous Non-Small Cell Lung Cancer 6Melanoma 6Lymphoma, Non-Hodgkin 6Esophageal Neoplasms 6Lymphoma 5Thoracic Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 4

Interventions

Gemcitabine 2ruxolitinib 1rucaparib 1pemigatinib 1pembrolizumab 1motexafin gadolinium 1abiraterone 1Watchful Waiting 1Vorinostat 1Trastuzumab 1Tinzaparin 1TTI-621 1Rituximab 1Paclitaxel 1Nivolumab 1Ipilimumab 1In Situ Hybridization, Fluorescence 1INCB057643 1Fentanyl 1Epoetin Alfa 1Doxorubicin 1Docetaxel 1Cisplatin 1CTLA-4 Antigen 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Myeloproliferative Disorders × Gemcitabine × Thoracic × Clear all
NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
137 enrolled 31 charts
BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT02393248 2023-01-06

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Incyte Corporation

Phase 1/2 Terminated
201 enrolled 71 charts
BreastGastrointestinalGynecologicMyeloidPlasma cellThoracic

Breast Neoplasms, Lung Neoplasms, Multiple Myeloma, Myeloproliferative Disorders, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡